Talphera Hits Midpoint in CRRT Trial, Aims for 2026 FDA Filing
Event summary
- Talphera enrolls 35 of 70 patients in NEPHRO-CRRT trial, 90% from new target profile sites.
- FDA-approved trial changes in 2025 reduced patient count by 60%, accelerated enrollment.
- Company plans virtual investor event March 23 with nephrology experts to discuss CRRT needs.
- Niyad (nafamostat) seeks Breakthrough Device Designation for CRRT anticoagulation.
The big picture
Talphera's enrollment progress reflects successful trial redesign targeting ICU settings, addressing critical unmet needs in CRRT anticoagulation. The company's Breakthrough Device designation positions it to potentially become the first FDA-approved regional anticoagulant for this high-acuity indication, though it must navigate competitive pressures from off-label heparin use. The March 23 investor event will test physician advocates' ability to articulate clinical differentiation.
What we're watching
- Regulatory Pathway
- Whether Talphera can maintain accelerated FDA review timeline after trial redesign.
- Market Differentiation
- How Niyad's regional anticoagulant profile positions it against existing CRRT treatments.
- Commercialization Readiness
- The pace at which Talphera can secure ICD-10 coding adoption for nafamostat.
Related topics